Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial phase in negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move signals a strategic effort to combine two promising approaches in cancer therapy: DNA damage response (DDR) inhibition and immune checkpoint blockade.
The proposed collaboration aims to merge Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DDR therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. Unlike current LAG-3 therapies, which are monoclonal antibodies administered intravenously, Ifowonco's program focuses on orally available small-molecule inhibitors, offering potential advantages in patient convenience and dosing flexibility.
Under the terms of the LOI, the companies intend to evaluate the LAG-3 program independently. If preclinical findings are supportive, they will explore its use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program. This dual-pronged strategy could address the complex interplay between DNA repair mechanisms and immune evasion in tumors, potentially leading to more effective treatments.
Thomas O'Shaughnessy, CEO of Onco-Innovations, expressed optimism about the potential agreement, stating it could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." The move aligns with Onco's mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has already secured an exclusive worldwide license to patented technology targeting solid tumours, and this new initiative could further bolster its portfolio.
The LOI is non-binding, and a definitive agreement is not yet guaranteed. However, the announcement underscores Onco-Innovations' commitment to expanding its therapeutic reach and leveraging cutting-edge science to address unmet medical needs in oncology. For investors, this development highlights the company's proactive approach to building a diversified pipeline with potential synergies between different modalities.
For more details on the press release, visit https://ibn.fm/E63Ne. For the latest news and updates on Onco-Innovations, see https://ibn.fm/ONNVF.
